Literature DB >> 10658778

Epidemiology of nosocomial clostridium difficile diarrhoea.

M H Samore1.   

Abstract

Clostridium difficile is a frequent and clinically important cause of diarrhoea that has been strongly but not exclusively associated with the hospital setting. The vast majority of cases of C. difficile diarrhoea are associated with antecedent treatment with antibiotics, of which cephalosporins and clindamycin appear to pose the highest risk. Within hospitals and chronic-care facilities, cross-infection of C. difficile has been related to transient carriage on hands of healthcare workers and contamination of diverse environmental surfaces, including electronic rectal thermometers. Prospective epidemiologic studies have demonstrated that acquisition of C. difficile is common in hospitalized patients. Although colonized patients contribute to nosocomial transmission of C. difficile, symptom-free carriage of C. difficile appears to reduce risk of subsequent development of C. difficile diarrhoea. Antimicrobial treatment with oral metronidazole or vancomycin to attempt to eradicate symptomless carriage is not recommended. Measures to control nosocomial C. difficile diarrhoea have focused on improved handwashing, use of barrier precautions with single rooms for symptomatic patients, reduction of environmental contamination, and antibiotic restriction. Restricting clindamycin has been particularly successful in terminating outbreaks of C. difficile diarrhoea associated with its use. The epidemiologic features of C. difficile and strategies for control are similar to those for micro-organisms that have acquired antimicrobial resistance. C. difficile may be indirectly or directly contributing to spread of resistant organisms, for instance, by causing diarrhoea and thereby enhancing environmental contamination with other gastrointestinal flora such as vancomycin-resistant enterococci. Thus, a consideration of C. difficile in the larger context of the world-wide spread of antibiotic resistance offers useful insights that may help form the basis for the development of more effective control measures.

Entities:  

Mesh:

Year:  1999        PMID: 10658778     DOI: 10.1016/s0195-6701(99)90085-3

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  8 in total

1.  Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital.

Authors:  Olle Aspevall; Annika Lundberg; Lars G Burman; Thomas Akerlund; Bo Svenungsson
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

2.  2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.

Authors:  Jane D Siegel; Emily Rhinehart; Marguerite Jackson; Linda Chiarello
Journal:  Am J Infect Control       Date:  2007-12       Impact factor: 2.918

3.  Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A.

Authors:  Samer Aboudola; Karen L Kotloff; Lorraine Kyne; Michel Warny; Eoin C Kelly; Stavros Sougioultzis; Paul J Giannasca; Thomas P Monath; Ciarán P Kelly
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

4.  Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Authors:  Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

5.  [Antibiotic induced diarrhea and pseudomembranous colitis].

Authors:  C Greb; T Kalem; T Kälble
Journal:  Urologe A       Date:  2002-12-19       Impact factor: 0.639

6.  Epidemiology and molecular characterization of Clostridium difficile strains from patients with diarrhea: low disease incidence and evidence of limited cross-infection in a Swedish teaching hospital.

Authors:  Bo Svenungsson; Lars G Burman; Kirsti Jalakas-Pörnull; Asa Lagergren; Johan Struwe; Thomas Akerlund
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

7.  The identification and epidemiology of meticillin-resistant Staphylococcus aureus and Clostridium difficile in patient rooms and the ward environment.

Authors:  Meredith C Faires; David L Pearl; Olaf Berke; Richard J Reid-Smith; J Scott Weese
Journal:  BMC Infect Dis       Date:  2013-07-24       Impact factor: 3.090

8.  Mass antibiotic treatment for group A streptococcus outbreaks in two long-term care facilities.

Authors:  Andrea Smith; Aimin Li; Ornella Tolomeo; Gregory J Tyrrell; Frances Jamieson; David Fisman
Journal:  Emerg Infect Dis       Date:  2003-10       Impact factor: 6.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.